New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
04:55 EDTALKS, ALKS, RGDO, RGDO, LXRX, LXRX, ZIOP, ZIOP, RNA, RNA, AUXL, AUXL, XON, XON, SIGA, SIGA, GALE, GALE, MSTX, MSTXBiotech Industry Organization to hold a conference
16h Annual BIO CEO & Investor Conference is being held in New York on February 10-11.
News For ALKS;GALE;SIGA;XON;AUXL;RNA;ZIOP;LXRX;RGDO;MSTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
09:42 EDTZIOPZiopharm in talks with large drug companies, says BMO Capital
Subscribe for More Information
February 26, 2015
17:25 EDTZIOPZiopharm reports Q4 EPS (9c) with items, consensus (14c)
Subscribe for More Information
06:09 EDTZIOPStocks with implied volatility movement; NWBO ZIOP
Subscribe for More Information
February 25, 2015
15:51 EDTZIOPZiopharm March volatility elevated, March calls active
Subscribe for More Information
08:30 EDTALKSAlkermes price target raised to $79 from $75 at Leerink
Leerink raised its price target for Alkermes shares to $79 to reflect probability-of-success weighted ALKS 8700 in multiple sclerosis revenue. The firm views the company's Q4 results as strong, but notes its 2015 outlook missed consensus due to higher than expected operating expenses. Leerink says the 2015 guidance reflects Alkermes' maturing pipeline. It keeps an Outperform rating on the stock.
06:19 EDTALKSAlkermes pipeline eases loss of pain program, says Citigroup
Citigroup says Alkermes' pipeline programs and the continued growth of its base business help moderate the disappointment of the discontinuation of novel pain program ALKS-7106. Citi lowered its price target for Alkermes shares to $83 from $85 and keeps a Buy rating on the stock.
05:57 EDTALKSUBS says remain on sidelines with respect to Alkermes
Subscribe for More Information
February 24, 2015
10:59 EDTZIOPZiopharm March volatility elevated
Subscribe for More Information
10:06 EDTALKSHigh option volume stocks
High option volume stocks: CHGG LBTYK SMH RCAP NGLS OTEX TERP CNC ALKS AMT
08:56 EDTALKSOn The Fly: Pre-market Movers
Subscribe for More Information
08:54 EDTALKSAlkermes 7106 halt overshadows Q4 beat, says Credit Suisse
Subscribe for More Information
07:06 EDTALKSAlkermes sees FY15 adjusted EPS 27c-40c, consensus 20c
Subscribe for More Information
07:03 EDTALKSAlkermes reports Q4 EPS 11c, consensus 4c
Subscribe for More Information
07:01 EDTALKSAlkermes announces phase 1 results for ALKS 7106, will not proceed to phase 2
Subscribe for More Information
February 23, 2015
16:34 EDTLXRXLexicon Chief Scientific Officer resigns
Lexicon Pharmaceuticals announced the resignation of Brian Zambrowicz, Ph.D., executive vice president and Chief Scientific Officer, to pursue another opportunity. Dr. Zambrowicz will be assisting in shifting his responsibilities to other members of the company in order to ensure a seamless transition. In connection with the change, Lexicon will merge its discovery and clinical functions and conduct an immediate search for a head of research and development. Dr. Zambrowicz has agreed to be available to provide consulting services as the company completes this transition.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use